2026-02-17 12:00:53
Latest Post
Texmaco Rail & Engineering Ltd receives order worth Rs. 219.18 crores
HFCL secures Purchase Orders worth ~INR 60.95 crore for supply of Optical Fiber Cables
Highway Infrastructure Ltd receives LoA of Rs. 154.59 crores
EKI Energy Services Ltd featured among Top Global Renewable Energy Carbon Credit Suppliers in Abatable's 2026 Carbon Market Report
Shraddha Prime Projects Ltd to enter into Development Agreement for new project
Stock Report
Ind-Swift Laboratories allocates ₹40 Cr for Samba Facility Upgrade
Posted On : 2026-02-16 15:45:39( TIMEZONE : IST )
Ind-Swift Laboratories Limited, based in Chandigarh, has approved a ₹400 million capital investment to upgrade its finished dosage manufacturing facility in Samba, Jammu & Kashmir. This strategic enhancement targets EU-GMP and PIC/S compliance, positioning the unit to penetrate regulated export markets like Europe, the UK, Australia, Canada, and South Africa.
Key Upgrade Objectives and Timeline
The project focuses on elevating environmental sustainability, material governance, and utility reliability while minimizing manual intervention, bolstering data integrity, and ensuring process robustness. Upgrades are slated for completion within 8-12 months, followed by EU GMP approval in another 8-9 months. Post-certification, the company plans to file 15-20 molecules across target regions.
Currently, the facility serves the domestic market through its ointment section (own brands and contract manufacturing) and other forms like tablets, capsules, and dry syrups, generating ₹360 million in annual sales with a 10% average bottom line.
Projected Financial Impact
From FY 2027-28, Ind-Swift anticipates the upgraded unit to deliver ₹750-800 million in sales, achieving robust 18-20% profit margins. This export push aligns with rising global demand, transforming the facility into a high-margin growth engine.
Mr. Sahil Munjal, Managing Director (Exports), affirmed: "We are witnessing increased demand for our products in the export markets. The upgradation of the Jammu facility will enable us to expand our product portfolio in Europe, UK, Australia and other markets, significantly strengthening our global footprint."
This initiative underscores Ind-Swift's focus on regulatory excellence, scalable operations, patient safety, and long-term sustainability in the competitive pharmaceutical landscape.
Shares of Ind-Swift Laboratories Limited was last trading in BSE at Rs. 135.80 as compared to the previous close of Rs. 135.10. The total number of shares traded during the day was 22804 in over 533 trades.
The stock hit an intraday high of Rs. 140.70 and intraday low of 131.30. The net turnover during the day was Rs. 3107616.00.
